Status:

COMPLETED

Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects

Lead Sponsor:

co.don AG

Conditions:

Articular Cartilage Lesion of the Femoral Condyle

Eligibility:

All Genders

18-50 years

Phase:

PHASE3

Brief Summary

This is a prospective, phase III, multicenter, open label, randomised clinical trial of co.don chondrosphere®, a three-dimensional autologous chondrocyte transplantation product (ACT3D-CS)compared to ...

Detailed Description

see above

Eligibility Criteria

Inclusion

  • Male or female patients, age: between 18 and 50 years
  • Defect: isolated ICRS grade III or IV single defect chondral lesions on femoral condyles
  • Defect size: 1 to \< 4 cm2 after debridement to healthy cartilage up to 6 mm in depth.Assessment with MRI at screening and per estimation during arthroscopy prior to randomization
  • Nearly intact chondral structure surrounding the defect as well as an intact corresponding joint area
  • Informed consent signed and dated by patient
  • Patient understands the strict rehabilitation protocol and follow-up programme and is willing to follow it
  • In case of pain, patient agrees to use only paracetamol mono- (max 4 g/day) or combination preparation and oral and/or topic NSAIDs during the trial and to discontinue the use of oral and/or topic NSAIDs and/or paracetamol combination preparation 1 week before each visit whereas the use of paracetamol monopreparation (max 4 g/day) is allowed. However, in the morning of the visit day, no pain medication is allowed. Other pain medications are allowed during surgical procedure and may be taken for a period not exceeding 4 weeks after surgery.

Exclusion

  • Defects on both knees at the same time
  • Radiological signs of osteoarthritis
  • Osteochondritis dissecans (OCD)
  • Any signs of knee instability
  • Valgus or varus malalignment (more than 5° over the mechanical axis)
  • Clinically relevant second cartilage lesion on the same knee
  • More than 50 % resection of a meniscus in the affected knee or incomplete meniscal rim
  • Rheumatoid arthritis, parainfectious or infectious arthritis, and condition after these diseases
  • Pregnancy and planned pregnancy (no MRI possible)
  • Obesity (Body Mass Index \>30)
  • Uncontrolled diabetes mellitus
  • Serious illness
  • Poor general health as judged by physician
  • Participation in concurrent clinical trials or previous trials within 3 months of screening
  • Previous treatment with ACT in the affected knee
  • Microfracture performed less than 1 year before screening in the affected knee
  • Alcohol or drug (medication) abuse
  • Meniscal transplant in the affected knee
  • Meniscal suture (in the affected knee) three months prior to baseline
  • Mosaicplasty (Osteoarticular Transplant System, OATS) in the affected knee
  • Having received hyaluronic acid intra-articular injections in the affected knee within the last 3 months before baseline
  • Taking specific osteoarthritis drugs such as chondroïtin sulfate, diacerein, nglucosamine,piascledine, capsaicin within 2 weeks before baseline
  • Corticosteroid treatment by systemic or intraarticular route within the last month of baseline or intramuscular or oral corticosteroïds within the last 2 weeks before baseline
  • Chronic use of anticoagulants
  • Any concomitant painful or disabling disease of the spine, hips or lower limbs that would interfere with evaluation of the afflicted knee
  • Any clinically significant or symptomatic vascular or neurological disorder of the lower extremities
  • Any evidence of the following diseases in the affected knee: septic arthritis, inflammatory joint disease, recurrent episodes of pseudogout, Paget's disease of bone, ochronosis, acromegaly, haemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders, collagen gene mutation
  • Current diagnosis of osteomyelitis, human immunodeficiency virus (HIV-1,-2) and/or hepatitis C virus (HCV) infection

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2020

Estimated Enrollment :

102 Patients enrolled

Trial Details

Trial ID

NCT01222559

Start Date

October 1 2010

End Date

February 1 2020

Last Update

January 27 2021

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Universitätsklinikum der Albert-Ludwig-Universität Freiburg, Department Othopädie und Traumatologie

Freiburg im Breisgau, Baden-Würrtemberg, Germany, 79106

2

Waldkrankenhaus "Rudolf Elle" GmbH Klinik für Orthopädie und Unfallchirurgie

Eisenberg, Tühringen, Germany, 07607

3

Gelenk-und Wirbelsäulenzentrum Steglitz

Berlin, Germany, 12163

4

DRK-Kliniken Westend

Berlin, Germany, 14050